文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

用于研究 Kras 驱动的肺腺癌中抗肿瘤 T 细胞反应的小鼠模型。

A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma.

机构信息

Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06519, USA.

Lead contact.

出版信息

Cell Rep Methods. 2021 Sep 27;1(5). doi: 10.1016/j.crmeth.2021.100080. Epub 2021 Sep 16.


DOI:10.1016/j.crmeth.2021.100080
PMID:34632444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8500377/
Abstract

Kras-driven lung adenocarcinoma (LUAD) is the most common lung cancer. A significant fraction of patients with Kras-driven LUAD respond to immunotherapy, but mechanistic studies of immune responses against LUAD have been limited because of a lack of immunotherapy-responsive models. We report the development of the immunogenic KP × NINJA (inversion inducible joined neoantigen) (KP-NINJA) LUAD model. This model allows temporal uncoupling of antigen and tumor induction, which allows one to wait until after infection-induced inflammation has subsided to induce neoantigen expression by tumors. Neoantigen expression is restricted to EPCAM+ cells in the lung and expression of neoantigen was more consistent between tumors than when neoantigens were encoded on lentiviruses. Moreover, tumors were infiltrated by tumor-specific CD8 T cells. Finally, LUAD cell lines derived from KP-NINJA mice were immunogenic and responded to immune checkpoint therapy (anti-PD1 and anti-CTLA4), providing means for future studies into the immunobiology of therapeutic responses in LUAD.

摘要

Kras 驱动的肺腺癌 (LUAD) 是最常见的肺癌。相当一部分 Kras 驱动的 LUAD 患者对免疫疗法有反应,但由于缺乏免疫治疗反应模型,针对 LUAD 的免疫反应的机制研究一直受到限制。我们报告了免疫原性 KP × NINJA(反转诱导连接新抗原)(KP-NINJA)LUAD 模型的开发。该模型允许抗原和肿瘤诱导的时间解耦,这使得人们可以等到感染诱导的炎症消退后,再通过肿瘤诱导新抗原表达。新抗原仅在肺中的 EPCAM+细胞中表达,并且与将新抗原编码在慢病毒上相比,肿瘤之间的新抗原表达更为一致。此外,肿瘤被肿瘤特异性 CD8 T 细胞浸润。最后,源自 KP-NINJA 小鼠的 LUAD 细胞系具有免疫原性,并对免疫检查点治疗(抗 PD1 和抗 CTLA4)有反应,为未来研究 LUAD 治疗反应的免疫生物学提供了手段。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/e6d3e7c8e29a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/6f39fc3ae650/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/b07da0366603/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/18cf9a50856e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/239b616707c8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/83d8ec51a3b9/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/e6d3e7c8e29a/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/6f39fc3ae650/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/b07da0366603/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/18cf9a50856e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/239b616707c8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/83d8ec51a3b9/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ad/9017202/e6d3e7c8e29a/gr5.jpg

相似文献

[1]
A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma.

Cell Rep Methods. 2021-9-27

[2]
Protein kinase Cι mediates immunosuppression in lung adenocarcinoma.

Sci Transl Med. 2022-11-16

[3]
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.

Mol Cancer. 2024-4-20

[4]
Comprehensive analysis and identification of subtypes and hub genes of high immune response in lung adenocarcinoma.

BMC Pulm Med. 2024-7-4

[5]
Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.

J Thorac Oncol. 2019-2-12

[6]
Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS-driven lung adenocarcinoma.

Nat Commun. 2023-9-20

[7]
Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1.

J Exp Clin Cancer Res. 2022-10-8

[8]
EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.

Aging (Albany NY). 2020-12-3

[9]
Inducible de novo expression of neoantigens in tumor cells and mice.

Nat Biotechnol. 2021-1

[10]
Redox phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma.

Oncoimmunology. 2024

引用本文的文献

[1]
Tissue-specific properties of type 1 dendritic cells in lung cancer: implications for immunotherapy.

J Immunother Cancer. 2025-3-25

[2]
KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection.

Science. 2025-1-2

[3]
Fuel for thought: targeting metabolism in lung cancer.

Transl Lung Cancer Res. 2024-12-31

[4]
Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.

J Natl Cancer Inst. 2025-4-1

[5]
Mouse Models Enable the Functional Investigation of Tertiary Lymphoid Structures in Cancer.

Methods Mol Biol. 2025

[6]
Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity.

Cell. 2024-10-31

[7]
Non-invasive detection of orthotopic human lung tumors by microRNA expression profiling of mouse exhaled breath condensates and exhaled extracellular vesicles.

Extracell Vesicles Circ Nucl Acids. 2024

[8]
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.

Cancer Res. 2024-4-15

[9]
Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors.

J Immunol. 2024-2-15

[10]
An optimized protocol for the generation and monitoring of conditional orthotopic lung cancer in the KP mouse model using an adeno-associated virus vector compatible with biosafety level 1.

Cancer Immunol Immunother. 2023-12

本文引用的文献

[1]
A reservoir of stem-like CD8 T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response.

Sci Immunol. 2021-10

[2]
Therapeutic depletion of CCR8 tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.

J Immunother Cancer. 2021-2

[3]
Cancer Statistics, 2021.

CA Cancer J Clin. 2021-1

[4]
The Effect of Advances in Lung-Cancer Treatment on Population Mortality.

N Engl J Med. 2020-8-13

[5]
Inducible de novo expression of neoantigens in tumor cells and mice.

Nat Biotechnol. 2021-1

[6]
Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.

Cancer Cell. 2020-3-16

[7]
Immune Responses to Viral Gene Therapy Vectors.

Mol Ther. 2020-1-10

[8]
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC.

Life Sci Alliance. 2019-5-27

[9]
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.

Cancer Cell. 2019-4-8

[10]
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in -Mutant Non-Small Cell Lung Cancer.

Cancer Immunol Res. 2018-8-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索